l e t t e r s Alternating hemiplegia of childhood (AHC) is a rare, severe neurodevelopmental syndrome characterized by recurrent hemiplegic episodes and distinct neurological manifestations. AHC is usually a sporadic disorder and has unknown etiology. We used exome sequencing of seven patients with AHC and their unaffected parents to identify de novo nonsynonymous mutations in ATP1A3 in all seven individuals. In a subsequent sequence analysis of ATP1A3 in 98 other patients with AHC, we found that ATP1A3 mutations were likely to be responsible for at least 74% of the cases; we also identified one inherited mutation in a case of familial AHC. Notably, most AHC cases are caused by one of seven recurrent ATP1A3 mutations, one of which was observed in 36 patients. Unlike ATP1A3 mutations that cause rapid-onset dystonia-parkinsonism, AHC-causing mutations in this gene caused consistent reductions in ATPase activity without affecting the level of protein expression. This work identifies de novo ATP1A3 mutations as the primary cause of AHC and offers insight into disease pathophysiology by expanding the spectrum of phenotypes associated with mutations in ATP1A3.
AHC was first characterized as a distinct syndrome in 1971, with a report that described eight patients with episodes of intermittent hemiplegia on alternating sides of the body, developmental delay, dystonia and choreoathetosis beginning in infancy 1 . Since then, specific diagnostic criteria have more clearly defined the classic paroxysmal and interictal neurological manifestations associated with this disease 2-6 . AHC affects approximately 1 in 1 million individuals 7 , with most cases occurring sporadically 5, [8] [9] [10] . Although the etiology of AHC is usually unknown, a missense mutation in ATP1A2 was reported in one case of atypical familial alternating hemiplegia 9,10 ; however, the clinical presentation of some of the family members with the ATP1A2 mutation was more consistent with familial hemiplegic migraine 9 , which is caused by mutations in ATP1A2 (refs. 11,12) . To our knowledge, no cases of sporadic AHC have yet been attributed to ATP1A2 mutations.
In this study, we used next-generation sequencing (NGS) of the exomes or whole genomes of ten individuals with AHC and, where possible, their unaffected parents. We identified and confirmed rare (minor allele frequency (MAF) <0.01%) mutations in ATP1A3 (encoding the sodium-potassium (Na + /K + ) ATPase α3 subunit, also known as ATP1A3) in eight of ten probands, and we showed that the mutations had occurred de novo in the seven patients for whom parental DNA was available. The ATP1A3 mutations included five distinct nonsynonymous mutations, one of which was found in four patients with AHC ( Supplementary Table 1 ). To further investigate ATP1A3 in the two unexplained AHC probands, we looked for structural variants in the whole-genome sequence data, and we Sanger sequenced the proteinencoding exons to find single-nucleotide and insertion-deletion variants missed by whole-genome sequencing; neither analysis identified candidate causal ATP1A3 mutations in these individuals. Given the rarity of functional de novo mutations, the occurrence of seven de novo mutations in the same gene in seven patients with AHC provides strong genetic evidence that mutations in ATP1A3 cause sporadic AHC.
We next Sanger sequenced the protein-encoding exons of ATP1A3 in an additional cohort of 95 individuals with AHC. In these 95 patients, we identified rare ATP1A3 mutations in 74 patients ( Table 1) ; these mutations were found to have arisen de novo in the 59 patients with sporadic AHC for whom parental DNA was available. Including samples sequenced with NGS, we identified a total of 19 different ATP1A3 mutations in 82 of 105 (78%) patients studied. The majority of these mutations were located in or near regions encoding transmembrane domains ( Fig. 1) . Seven of the mutations were identified in multiple cases of AHC; in particular, those giving rise to amino acid substitutions D801N and E815K were identified in 36 (34%) patients and 19 (18%) patients, respectively ( Table 1) . One of the 95 patients evaluated had a familial form of alternating hemiplegia, first described in 1992 (ref. 8) . In this individual, we identified a rare ATP1A3 mutation (giving rise to I274N) affecting the encoded cytoplasmic domain that cosegregates with the AHC phenotype ( Fig. 2; see Supplementary Note for phenotypic details of affected family members).
Thirteen of the 18 ATP1A3 mutations seen in sporadic AHC cases were confirmed to be de novo ( Supplementary Table 1 ). We also observed rare ATP1A3 variants in 15 patients with sporadic AHC for whom parental DNA was not available, and it is possible that some of these mutations are inherited benign polymorphisms. This is unlikely given the rarity of functional variants in ATP1A3, but we can conservatively estimate the number of patients with pathogenic ATP1A3 mutations by considering as pathogenic only those mutations observed as de novo in at least one patient. Under this criterion, 11 of the 15 patients have a pathogenic ATP1A3 mutation. We can, therefore, conclude that at least 74% of patients with sporadic, typically presenting AHC studied here harbor disease-causing mutations in ATP1A3. l e t t e r s ATP1A3 is an α subunit of the Na + /K + ATPase pump that is partly responsible for establishing and maintaining electrochemical gradients of sodium and potassium ions across the plasma membrane of neurons 13 . Mutations in ATP1A3 have been shown to cause rapid-onset dystonia-parkinsonism (DYT12) [14] [15] [16] [17] [18] . None of the mutations known to cause DYT12 was found in patients with AHC; however, two AHCcausing mutations (encoding D801N and I274N) affect amino acids also affected by DYT12-causing mutations.
To better understand how ATP1A3 mutations cause two clinically distinct disorders, we studied the in vitro functional consequences of the five mutations identified in the NGS screens of patients with AHC and ten mutations that cause DYT12. All 15 mutations were introduced in expression constructs, transfected into COS-7 and HeLa cells, and assessed for ATP1A3 expression and function. None of the mutations was found to affect ATP1A3 mRNA expression ( Supplementary Fig. 1) .
However, seven out of ten mutations that cause DYT12 reduced ATP1A3 protein expression to undetectable levels, whereas none of the AHC-causing mutations reduced protein expression compared to wild-type ATP1A3 ( Fig. 3 and Supplementary Fig. 2) . Despite having different effects on protein expression, both mutations that cause AHC and those that cause DYT12 reduced ATP1A3 in vitro by 54-90% ( Fig. 3) . We note that the previous study of ATP1A3 expression in DYT12 reported that protein expression was attenuated by the D801Y substitution and not affected by the I274T substitution 14 , whereas we observe opposite effects in our study. This discrepancy may be attributed to different sensitivities of the assay in specific cell lines. Despite this inconsistency, DYT12-causing mutations typically reduced ATP1A3 protein expression in both studies, whereas in our study no AHC-causing mutation reduced protein levels. Because hypomorphic mutations would lead to reduced protein abundance and modifications that are distributed throughout the protein rather than concentrated in transmembrane domains, these data suggest that ATP1A3 mutations causing AHC modulate the Na + /K + ATPase pump's activity, whereas DYT12-causing mutations do so through hypomorphic effects on the pump. Further supporting this hypothesis, evaluation of the crystal structure of the Na + /K + ATPase 19 predicts that a D801N substitution in AHC will prevent the binding of potassium ions to the Na + /K + ATPase pump. One possible exception to this pattern is the de novo splice-site mutation observed in a patient with AHC, which may result in protein elimination by a frameshift, although it could also result in a protein with altered activity.
As noted above, seven of the 19 AHC-causing mutations were observed in multiple patients. A recurrent mutation in FGFR3 was previously reported to cause the majority of cases of achondroplasia 20 , suggesting the presence of a hypermutable sequence in that gene. In AHC, the recurrence of de novo mutations may be a result of hypermutable sequences in ATP1A3, the ascertainment effect of only a specific subset of mutations causing AHC, or both. Some contribution of hypermutability is indicated by the following analysis: we observed 13 sites that carry de novo mutations in ATP1A3; under the null hypothesis that the mutation rate is equal among these sites, the chance that any single mutation would be seen in at least 36 of the total 77 patients found to have a 'pathogenic' mutation (as observed for the mutation giving rise to D801N) is low (P < 0.0001). Furthermore, three of the seven recurrently mutated sites found in AHC are G>A substitutions npg l e t t e r s occurring at hypermutable methylated CpG-dinucleotide sequences 21 ( Table 1 ). It also seems that only a specific subset of ATP1A3 mutations lead to AHC, as nearly all identified AHC-causing mutations affect regions in or near transmembrane domains of the encoded protein, whereas the DYT12 mutations are more evenly distributed (Fig. 1) . These results suggest that the observed patterns of AHC-causing mutations across ATP1A3 result from hypermutable sequences and that only a small set of specific mutations can cause AHC. This is consistent with functional analyses suggesting that AHC-causing mutations may have specific effects on protein function rather than simply decreasing protein activity. Although not done in this study, functional evaluation of the inherited ATP1A3 mutation (giving rise to I124N) may reveal distinct effects on the activity of Na + /K + ATPase that may help to explain the atypical familial AHC phenotype.
Myshkin mice, which are heterozygous for a missense Atp1a3 mutation (encoding a I810N substitution) that inactivates Na + /K + ATPase, are predisposed to seizure activity that can be mitigated by replacement of the gene with functional Atp1a3 (ref. 22) . We therefore evaluated whether patients with ATP1A3 mutations were more likely to have seizures than those without, and found a minor but significant effect (54% of those with ATP1A3 mutations had a history of seizures, compared to 29% of those without; P = 0.01, binomial probability calculation). For one patient cohort (n = 30) for which consistent phenotyping had been done 5 , we also compared age at first paroxystic event, age at first hemiplegic attack and a series of disability indices but found no statistically significant differences between those with and without ATP1A3 mutations. More detailed investigations are needed to characterize the phenotypic spectrum associated with ATP1A3 mutations and to compare phenotypes among patients with different ATP1A3 mutations.
Mutations in ATP1A3 probably account for at least 74% of cases of typical sporadic AHC. Because the present study assessed only patients with typical AHC, further work will be needed to assess whether ATP1A3 mutations cause distinct, but related, conditions. In addition to identifying the cause of the majority of AHC cases, our results now implicate another clinically distinct disease linked to ATP1A3 and open the door to detailed functional characterization of mutations that cause the different diseases. The ability to test the functional consequences of two groups of mutations that lead to clinically distinct phenotypes will offer insight into the pathophysiological processes unique to each disease and could facilitate drug discovery for these and related conditions. 
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